{"id":"cabotegravir-rilpivirine-drug-combination","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:16:02.803243","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human chromosomes. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the enzyme responsible for converting HIV RNA into DNA. Together, they provide dual-mechanism antiretroviral activity for HIV treatment and prevention.","oneSentence":"This combination inhibits HIV integrase and reverse transcriptase to prevent viral replication and integration into host DNA.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:39.062Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection treatment"},{"name":"HIV-1 pre-exposure prophylaxis (PrEP)"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT05991622","phase":"PHASE2","title":"Combined Injectable Treatment for HIV and OUD","status":"WITHDRAWN","sponsor":"Rhode Island Hospital","startDate":"2022-04-01","conditions":"Human Immunodeficiency Virus, Opioid Use Disorder","enrollment":""},{"nctId":"NCT03497676","phase":"PHASE1, PHASE2","title":"More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-03","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT04982445","phase":"PHASE4","title":"Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-11-18","conditions":"HIV Infections","enrollment":44},{"nctId":"NCT06704204","phase":"","title":"Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community","status":"NOT_YET_RECRUITING","sponsor":"The Miriam Hospital","startDate":"2025-02","conditions":"HIV","enrollment":20},{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT06507059","phase":"PHASE3","title":"Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2024-07-19","conditions":"HIV-1-infection, Non-Adherence, Medication","enrollment":40},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT04542070","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-11-09","conditions":"HIV Infections","enrollment":687},{"nctId":"NCT06403865","phase":"","title":"Patient-Reported Outcomes in Real-life of Cabotegravir and Rilpivirine","status":"NOT_YET_RECRUITING","sponsor":"University Paris 7 - Denis Diderot","startDate":"2024-05","conditions":"Quality of Life","enrollment":280},{"nctId":"NCT05154747","phase":"PHASE3","title":"Long-Acting Treatment in Adolescents (LATA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2023-06-22","conditions":"Hiv, HIV Infections, HIV-1-infection","enrollment":476}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2025 Jun 26","pmid":"40146807","title":"Cabotegravir/rilpivirine resistance in a patient living with HIV despite on-time administration: A case report.","journal":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CAB","RPV"],"phase":"phase_3","status":"active","brandName":"Cabotegravir, Rilpivirine Drug Combination","genericName":"Cabotegravir, Rilpivirine Drug Combination","companyName":"University Paris 7 - Denis Diderot","companyId":"university-paris-7-denis-diderot","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV integrase and reverse transcriptase to prevent viral replication and integration into host DNA. Used for HIV-1 infection treatment, HIV-1 pre-exposure prophylaxis (PrEP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}